Morgan Stanley analyst Tejas Savant maintains $Natera (NTRA.US)$ with a buy rating, and maintains the target price at $176.
According to TipRanks data, the analyst has a success rate of 40.0% and a total average return of -4.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Natera (NTRA.US)$'s main analysts recently are as follows:
The stock's valuation is seen as fully warranted by several catalysts that are expected to drive both near-term and long-term upside in estimates. This view is based on the recent quarterly results, the updated projections for 2024, and the initial insights provided for 2025 during the management's discussion.
Natera has reported yet another robust quarter, according to an analyst. It is noted that the company is excelling across various metrics, including volume, selling price, margin, and cash management, with potential for even greater enhancements looking towards 2025. The sustained strong performance reinforces the belief that Natera stands out as a premier entity within the diagnostics sector.
The company's Q3 results were exceptionally strong, continuing the trend of improving fundamentals. The company is channeling its operating cash flow back into the business, thereby strengthening its leadership in sales, marketing, medical affairs, and legal aspects.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
摩根士丹利分析师Tejas Savant维持$Natera (NTRA.US)$买入评级，维持目标价176美元。
根据TipRanks数据显示，该分析师近一年总胜率为40.0%，总平均回报率为-4.5%。
此外，综合报道，$Natera (NTRA.US)$近期主要分析师观点如下：
股票的估值被认为是完全合理的，预计将推动短期和长期预期的增长的几个催化剂支撑。这一观点基于最近的季度业绩，2024年更新的预测，以及管理层讨论中对2025年初步提供的见解。
根据一位分析师的说法，Natera又一季度表现强劲。据悉，该公司在各种指标上表现出色，包括成交量、售价、利润率和现金管理，展望2025年有更大的提升潜力。持续强劲的业绩强化了Natera在诊断板块中独树一帜的信念。
公司第三季度的业绩异常强劲，延续了基本面不断改善的趋势。该公司将经营性现金流重新投入业务，进一步加强其在销售、营销、医疗事务和法律方面的领导地位。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
